Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
Koeberle, D. ; Betticher, D. C. ; von Moos, R. ; Dietrich, D. ; Brauchli, P. ; Baertschi, D. ; Matter, K. ; Winterhalder, R. ; Borner, M. ; Anchisi, S. ; Moosmann, P. ; Kollar, A. ; Saletti, P. ; Roth, A. ; Frueh, M. ; Kueng, M. ; Popescu, R. A. ; Schacher, S. ; Hess, V. ; Herrmann, R.
In: Annals of Oncology, 2015, vol. 26, no. 4, p. 709-714
Aggiungi alla tua lista- Summary
- In this trial, stopping bevacizumab after completion of induction chemotherapy was associated with a shorter time to progression, but no statistically significant difference in overall survival compared with the bevacizumab continuation strategy. Non-inferiority could not be demonstrated. Treatment costs are substantially higher for continuous bevacizumab treatment